Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein zwilch homolog (ZWILCH)
- Target
- ZWILCH
- Molecular classification
- Kinetochore protein, Mitotic checkpoint protein, Scaffold protein (component of RZZ complex), Other
01
Overview
Protein zwilch homolog (ZWILCH) is an essential component of the ROD-Zwilch-ZW10 (RZZ) complex, which assembles as a fibrous corona structure on the outer kinetochore during mitosis[2][4][9]. This complex is critical for the recruitment of dynein-dynactin motors and spindle assembly checkpoint proteins (MAD1-MAD2) to kinetochores, ensuring correct chromosome-microtubule interactions and regulating the accurate timing of anaphase onset[1][3][4][5][7][9]. ZWILCH is evolutionarily conserved from Drosophila to humans and localizes to kinetochores and kinetochore microtubules during cell division[1][7][8]. Mutations or dysfunction of ZWILCH disrupts kinetochore attachment and spindle checkpoint integrity, thereby promoting lagging chromosomes, aneuploidy, and other mitotic failures—a phenotype linked to cancer development[1][7][9]. The RZZ complex provides an assembly and signaling platform for proteins governing chromosome segregation and spindle assembly checkpoint fidelity.
- Other names
- ZWILCHhZwilchFLJ10036KNTC1APProtein zwilch homologZwilch, kinetochore associatedHomolog of Drosophila Zwilch
02
Mechanism of action
null
03
Biological functions
Kinetochore assemblyChromosome segregation during mitosisSpindle checkpoint signalingRecruitment of dynein-dynactin and MAD1-MAD2 complexes to kinetochoresPrevention of premature mitotic exit[1][3][4][5][7][9]
04
Disease associations
Cancer (potentially due to its role in chromosome segregation and mitotic checkpoint defects)Other (defective chromosome segregation can contribute to aneuploidy, a cancer hallmark)[1][7][9]
05
Safety considerations
Disruption of ZWILCH may lead to chromosome missegregation, aneuploidy, and/or cell cycle arrest[1][7][9]Therapeutic targeting could cause off-target effects in dividing cells, raising risks for cytotoxicity and tissue regeneration defects.
06
Biomarkers
Defects in ZWILCH (or the RZZ complex) may serve as potential biomarkers for chromosomal instability or mitotic checkpoint dysfunction in cancer research, but no routine clinical biomarkers are documented for ZWILCH[1][4][9]
Beyond the preview
Go deeper on Protein zwilch homolog (ZWILCH).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein zwilch homolog (ZWILCH).